Replies to post #364119 on NorthWest Biotherapeutics Inc (NWBO)

[B52T38]

Hello, biosectinvestor, I'm a fairly recent investor in NWBO and my question is - besides the acquisition of production capacity in the UK, what is the best evidence that supports your thesis of "exciting" TLD?"

Appreciate your opinion(s).

[marzan]

Bio/Gary/ATL, I wish Bill Malloy interviews LL again now that I bet LL will say she is now satisfied with the progress LP made that DCVaxL therapy can be scaled to any large manufacturing capacity with the Flaskworks now joining the assembly line or so, imo. Recall she was worried about personalized therapy such as DcVaxL has its inherent weakness that manufacturing it in a mass scale to meet the demand could be challenging. LP went after every 'if and buts' of such reasonable worries that she has fixed that issue now I guess in the CDMO arena in the U.S. gearing the CRL purchase of Cognate, and Sawston/Avent development in the Europe. One another worry LL expressed in that interview was the option available about patenting dendritic cell therapy with the Use and Composition methods that no one can beat LP et al in this regard that they have a fortress of Use & Composition patents now; I bet including the combo one with the CI that could be the best to be approved any day. I bet LL is so happy now that she is into publishing her findings via TLD, ASCO, and of course the Elsevier pub that is coming out on the 28th of April. LP is the master strategist! Go NWBO!!